180 related articles for article (PubMed ID: 25245280)
1. Amphipathic tail-anchoring peptide is a promising therapeutic agent for prostate cancer treatment.
De G; Ko JK; Tan T; Zhu H; Li H; Ma J
Oncotarget; 2014 Sep; 5(17):7734-47. PubMed ID: 25245280
[TBL] [Abstract][Full Text] [Related]
2. Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 (BH3) peptides from Bcl-2 family proteins induce apoptosis through different mechanisms.
Ko JK; Choi KH; Peng J; He F; Zhang Z; Weisleder N; Lin J; Ma J
J Biol Chem; 2011 Mar; 286(11):9038-48. PubMed ID: 21189256
[TBL] [Abstract][Full Text] [Related]
3. The tail-anchoring domain of Bfl1 and HCCS1 targets mitochondrial membrane permeability to induce apoptosis.
Ko JK; Choi KH; Pan Z; Lin P; Weisleder N; Kim CW; Ma J
J Cell Sci; 2007 Aug; 120(Pt 16):2912-23. PubMed ID: 17666431
[TBL] [Abstract][Full Text] [Related]
4. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Activity of Thermosensitive Hydrogels Packaging Gambogic Acid Nanoparticles and Tumor-Penetrating Peptide iRGD Against Gastric Cancer.
Zhang D; Chu Y; Qian H; Qian L; Shao J; Xu Q; Yu L; Li R; Zhang Q; Wu F; Liu B; Liu Q
Int J Nanomedicine; 2020; 15():735-747. PubMed ID: 32099362
[TBL] [Abstract][Full Text] [Related]
6. Modification of IL-24 by tumor penetrating peptide iRGD enhanced its antitumor efficacy against non-small cell lung cancer.
Yang J; Yang J; Wei Y; Yin H; Fang L; Chai D; Li H; Li H; Zhang Q; Zheng J
Int Immunopharmacol; 2019 May; 70():125-134. PubMed ID: 30798161
[TBL] [Abstract][Full Text] [Related]
7. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
8. sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Sci Rep; 2017 Apr; 7(1):579. PubMed ID: 28373646
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer.
Yaghoubi A; Asgharzadeh F; Movaqar A; Ghazvini K; Hassanian SM; Avan A; Khazaei M; Soleimanpour S
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2851-2865. PubMed ID: 34117917
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer.
Wang F; Li B; Fu P; Li Q; Zheng H; Lao X
Int J Pharm; 2018 Aug; 547(1-2):611-620. PubMed ID: 29933059
[TBL] [Abstract][Full Text] [Related]
12. Core-shell nanoparticle-based peptide therapeutics and combined hyperthermia for enhanced cancer cell apoptosis.
Shah BP; Pasquale N; De G; Tan T; Ma J; Lee KB
ACS Nano; 2014 Sep; 8(9):9379-87. PubMed ID: 25133971
[TBL] [Abstract][Full Text] [Related]
13. iRGD-modified lipid-polymer hybrid nanoparticles loaded with isoliquiritigenin to enhance anti-breast cancer effect and tumor-targeting ability.
Gao F; Zhang J; Fu C; Xie X; Peng F; You J; Tang H; Wang Z; Li P; Chen J
Int J Nanomedicine; 2017; 12():4147-4162. PubMed ID: 28615942
[TBL] [Abstract][Full Text] [Related]
14. Zerumbone Induces Apoptosis in Breast Cancer Cells by Targeting αvβ3 Integrin upon Co-Administration with TP5-iRGD Peptide.
E M Eid E; S Alanazi A; Koosha S; A Alrasheedy A; Azam F; M Taban I; Khalilullah H; Sadiq Al-Qubaisi M; A Alshawsh M
Molecules; 2019 Jul; 24(14):. PubMed ID: 31337024
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Du R; Zhong T; Zhang WQ; Song P; Song WD; Zhao Y; Wang C; Tang YQ; Zhang X; Zhang Q
Int J Nanomedicine; 2014; 9():3091-105. PubMed ID: 25028548
[TBL] [Abstract][Full Text] [Related]
16. Tumor-penetrating iRGD peptide inhibits metastasis.
Sugahara KN; Braun GB; de Mendoza TH; Kotamraju VR; French RP; Lowy AM; Teesalu T; Ruoslahti E
Mol Cancer Ther; 2015 Jan; 14(1):120-8. PubMed ID: 25392370
[TBL] [Abstract][Full Text] [Related]
17. A modified thymosin alpha 1 inhibits the growth of breast cancer both in vitro and in vivo: suppressment of cell proliferation, inducible cell apoptosis and enhancement of targeted anticancer effects.
Lao X; Li B; Liu M; Shen C; Yu T; Gao X; Zheng H
Apoptosis; 2015 Oct; 20(10):1307-20. PubMed ID: 26283169
[TBL] [Abstract][Full Text] [Related]
18. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
19. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.
Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y
Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394
[TBL] [Abstract][Full Text] [Related]
20. Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy.
Huang Y; Li X; Sha H; Zhang L; Bian X; Han X; Liu B
Oncol Rep; 2017 Apr; 37(4):2063-2070. PubMed ID: 28260064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
